Amryt Pharma Share Chat (AMYT)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Amryt Pharma Plc	LSE:AMYT	London	Ordinary Share	GB00BKLTQ412	ORD 6P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	0.00	0.0%	122.50	120.00	125.00	122.50	122.50	122.50	16,738	08:00:00

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	13.0	-23.1	-8.4	-	266

Amryt Pharma Share Discussion Threads

Showing 5251 to 5274 of 5275 messages

Chat Pages: 211 210 209 208 207 206 205 204 203 202 201 200 Older

Date	Subject	Author	Discuss
13/11/2019 16:01	O/T. Big drop in the ECO share price today following the RNS. Glad I no longer dabble in speculative AIM O&G's. I'm just gambling on an AIM listed speculative biotech, AMYT, instead!	papillon	Read Full Thread Reply
11/11/2019 21:56	Two massive trades timed at just before 1pm, but only reported after the market closed. Both sells, but the share price responded by going up! I wonder if the trades have been worked over a number of days and have been depressing the share price and that now they have gone the share price will start to rise? These are the two trades: 400,000 @ 115.625p and timed @ 12:55:07. Proceeds £462,500,000 474,135 @ 115.50p and timed @ 12:54:15. Proceeds £547,630,000	papillon	Read Full Thread Reply
10/11/2019 18:03	hTTps://www.thetimes.co.uk/article/agenda-mystery-rises-as-bank-of-china-goes-for-irish-broker-goodbody-cttf2090r Wiley in the right with Amryt Perhaps you should have paid attention in biology class. Joe Wiley, chief executive, and Rory Nealon, chief financial officer, were last week granted options over 10.2m shares in Amryt Pharma, an Irish drug developer. The bumper share awards have an exercise price of £1.215p each. Amryt is an orphan drug specialist, finding treatments for rare diseases. The company recently acquired Aegerion, a Canadian peer and has a drug in development to treat the skin disease epidermolysis bullosa. There are no sure things in pharma, yet Wiley has a top reputation and a nose for a deal. The rewards here could be truly massive. Wiley by name, wily by nature. brian.carey@sunday-times.ie	papillon	Read Full Thread Reply
10/11/2019 17:19	Yep Sunday Times	alphabravo321	Read Full Thread Reply
10/11/2019 13:07	alphabravo321, you posted the following on the lse bb today. Does ST refer to the Sunday Times? tia alphabravo321 Posts: 33 Price: 121.00 No Opinion ST Today 05:30 Wiley in the right with Amryt Perhaps you should have paid attention in biology class. Joe Wiley, chief executive, and Rory Nealon, chief financial officer, were last week granted options over 10.2m shares in Amryt Pharma, an Irish drug developer. The bumper share awards have an exercise price of £1.215p each. Amryt is an orphan drug specialist, finding treatments for rare diseases. The company recently acquired Aegerion, a Canadian peer and has a drug in development to treat the skin disease epidermolysis bullosa. There are no sure things in pharma, yet Wiley has a top reputation and a nose for a deal. The rewards here could be truly massive. Wiley by name, wily by nature.	papillon	Read Full Thread Reply
06/11/2019 13:07	LOL, purple11. Don't forget to wake me up! "So wake me up when it's all over When I'm wiser and I'm older"	papillon	Read Full Thread Reply
06/11/2019 11:31	nite pappy	purple11	Read Full Thread Reply
06/11/2019 11:30	Back to sleep, until the next RNS.	papillon	Read Full Thread Reply
05/11/2019 22:37	https://www.irishtimes.com/business/health-pharma/dublin-pharma-company-amryt-grows-sales-almost-20-1.4072998?mode=amp	tiananmen	Read Full Thread Reply
05/11/2019 19:56	"It looks undervalued at less than 2 x full year sales. Cash helps but will get spent." Don't forget AMYT has debt, waterloo. The amount of debt must also be acknowledged in any attempt at valuing AMYT. Don't forget we've already had a broker note, waterloo. Stiffel's valuation dated 1st October. That was first posted by Bronxville on the lse bb and copied by me onto this bb last week (post 5087). Stiffel reckon … … … "that revenue-generative orphan drug companies trade at 8.8-times historic earnings." Seems rather fanciful to me, but even 4 x historic earnings valuation gives a 240p AMYT share price	papillon	Read Full Thread Reply
05/11/2019 19:24	£zillions........! Sorry, don’t have the expertise - guess that makes me a gambler and not an investor! At least I’m a very patient gambler.... Fingers very firmly crossed!	bazworth	Read Full Thread Reply
05/11/2019 18:55	Well at least they are not free options but have a strike price of £1.21. Makes them as keen as shareholders to see the share price climb. Would love to see a broker note. Any around? It looks undervalued at less than 2 x full year sales. Cash helps but will get spent. Hopefully the combined entity has a reasonable cost base. Any thoughts on appropriate valuation based on revenue now it's more visible?	waterloo01	Read Full Thread Reply
05/11/2019 18:48	Hope it’s positive!	bazworth	Read Full Thread Reply
05/11/2019 18:39	Timing of the options grant is telling in my opinion	alphabravo321	Read Full Thread Reply
05/11/2019 18:23	Big options grant for the lads	alphabravo321	Read Full Thread Reply
05/11/2019 17:17	Big buy just after 4pm. 106,352 @ 122.50p. Cost £130.28k.	papillon	Read Full Thread Reply
05/11/2019 14:23	ADVFN have blocked the link I posted in my previous post because of the word proactive in the link. So here is the YouTube link to the same video and Rory Nealon interview today. https://www.youtube.com/watch?v=dSxt_45OOPo&t=33s In the interview, alphabravo, Rory Nealon just states that a Nasdaq listing is under consideration. No firm date. No confirmation it will happen within the 90 day period since 24th September.	papillon	Read Full Thread Reply
05/11/2019 14:05	I am sticking with the commitment in the admission doc of seeking a Nasdaq listing within 90 days of deal closure which was Sep 24th.	alphabravo321	Read Full Thread Reply
05/11/2019 13:41	jupiternmars Posts: 1,286 Price: 121.50 No Opinion Rory Nealon - Proactive Today 13:16 [...] >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> It's well worth watching the video and listening to Rory Nealon being interviewed. The Nasdaq listing is commented on at the end of the interview by Nealon when questioned about it. It doesn't appear to be imminent.	papillon	Read Full Thread Reply
05/11/2019 12:39	Good sales figures, waterloo, but disappointed with the lack of news on the Nasdaq listing and a lower cash balance than I expected (US$61.2m = £47.44m at 31st October). Combined sales revenue of US$113.1m for the first 9 months of 2019 implies combined sales revenue of US$150.8m for the whole of 2019. That's inline with market expectations.	papillon	Read Full Thread Reply
05/11/2019 12:14	Yes noticeably absent. No idea why.	waterloo01	Read Full Thread Reply
05/11/2019 12:10	No mention of the Nasdaq listing in today's RNS. Cash balance of US$61.2m (£47.44m) @ 31st October.	papillon	Read Full Thread Reply
05/11/2019 11:12	surprised at the lack of trades here. Any broker notes or updates?	gucci	Read Full Thread Reply
05/11/2019 07:35	Results look excellent. Continued growth.	waterloo01	Read Full Thread Reply

Chat Pages: 211 210 209 208 207 206 205 204 203 202 201 200 Older

Your Recent History

LSE

AMYT

Amryt Phar..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.